Lethally aggressive multiply recurrent adamantinomatous craniopharyngioma without histological malignancy: illustrative cases.

Multiply recurrent ACP with a high Ki-67 LI can follow a rapidly lethal course despite benign histology. Early recognition of this aggressive phenotype should prompt short-interval MRI surveillance and timely, goal-directed salvage focused on proactive cyst control, hypothalamus-sparing strategies, and carefully selected reirradiation. When standard options fail, enrollment in clinical trials of emerging biological therapies, such as IL-6 blockade, intracystic peginterferon-α2a, and EGFR-axis treatments, should be considered. https://thejns.org/doi/10.3171/CASE25840.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-03-23
DOI
https://doi.org/10.3171/case25840
Primary Topic
Pituitary Gland Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lethally aggressive multiply recurrent adamantinomatous craniopharyngioma without histological malignancy: illustrative cases.

Masanori Goto, Hirokuni Hashikata, Yasunori Nagai, Yoshito Sugita et al.
PubMed
Pituitary Gland Disorders and Treatments
article

Lethally aggressive multiply recurrent adamantinomatous craniopharyngioma without histological malignancy: illustrative cases.

Masanori Goto, Hirokuni Hashikata, Yasunori Nagai, Yoshito Sugita, Takeshi Sawada, Noriyoshi Takebe, Koichi Iwasaki, Hiroki Toda, Yoshiaki Yuba, Naokado Ikeda
article en

Abstract

Multiply recurrent ACP with a high Ki-67 LI can follow a rapidly lethal course despite benign histology. Early recognition of this aggressive phenotype should prompt short-interval MRI surveillance and timely, goal-directed salvage focused on proactive cyst control, hypothalamus-sparing strategies, and carefully selected reirradiation. When standard options fail, enrollment in clinical trials of emerging biological therapies, such as IL-6 blockade, intracystic peginterferon-α2a, and EGFR-axis treatments, should be considered. https://thejns.org/doi/10.3171/CASE25840.

PubMedVol. 11(12)
Kitano Hospital (JP)
Good health and well-being
Openalex Percentile: Top 12%
Pituitary Gland Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.